ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

10 links0 made here, not in the record28 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govReplaced, or read an older version
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT06380751Saruparib (AZD5305) PlusCamizestrant or PlusEndocrine Therapy, ComparedWith CDK4/6 Inhibitor PlusEndocrine Therapy or PlusCamizestrant inHR-Positive, HER2-NegativeAstraZenecaPhase 3 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Oct 30 · ClinicalTrials.gov record · Version of 2026-10-30Version of 2026-10-30CONDITIONSBreast NeoplasmsNo longer in the registry's filing›Nov 14 · Rule based · Finest filed termAs of now · Rule based · Main conditionMain conditionDRUGSAZD5305Entry “Saruparib (AZD5305)”, read by …›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedAZD9833Entry “Camizestrant”, read by our nam…›Nov 3 · Claude Opus 5.5 · TestedNov 10 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedAbemaciclibIntervention entry›Nov 3 · Claude Opus 5.5 · TestedNov 3 · Claude Opus 5.5 · TestedNov 3 · Claude Opus 5.5 · Background · optionNov 3 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · TestedBackground · optionRibociclibIntervention entry›Nov 3 · Claude Opus 5.5 · TestedNov 3 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · TestedBackground · partnerPalbociclibIntervention entry›Nov 3 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · TestedBackground · partnerFulvestrantIntervention entry›Nov 3 · Claude Opus 5.5 · TestedNov 3 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · TestedComparatorLetrozoleIntervention entry›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedAnastrozoleIntervention entry›Nov 3 · Claude Opus 5.5 · TestedNov 10 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · TestedBackground · optionExemestaneIntervention entry›Nov 3 · Claude Opus 5.5 · TestedNov 10 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · TestedBackground · option

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

AZD5305

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Saruparib (AZD5305)”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Tested
Tested · 2

All judgments on this study

WhenLinkJudgeDecisionState
Oct 30The record itselfClinicalTrials.gov recordVersion of 2026-10-30Record change
Nov 3AZD5305Claude Opus 5.5TestedCurrent
Nov 3AZD9833Claude Opus 5.5TestedReplaced
Nov 3AbemaciclibClaude Opus 5.5TestedReplaced
Nov 3RibociclibClaude Opus 5.5TestedReplaced
Nov 3PalbociclibClaude Opus 5.5Background · partnerCurrent
Nov 3FulvestrantClaude Opus 5.5TestedReplaced
Nov 3LetrozoleClaude Opus 5.5TestedCurrent
Nov 3AnastrozoleClaude Opus 5.5TestedReplaced
Nov 3ExemestaneClaude Opus 5.5TestedReplaced
Nov 3AbemaciclibClaude Opus 5.5TestedReplaced
Nov 3AbemaciclibClaude Opus 5.5Background · optionReplaced
Nov 3RibociclibClaude Opus 5.5Background · partnerCurrent
Nov 3AbemaciclibClaude Opus 5.5Background · optionCurrent
Nov 3FulvestrantClaude Opus 5.5ComparatorCurrent
Nov 10AZD9833Claude Opus 5.5TestedCurrent
Nov 10AnastrozoleClaude Opus 5.5Background · optionCurrent
Nov 10ExemestaneClaude Opus 5.5Background · optionCurrent
Nov 14Breast NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 18AZD5305Rule based · role ruleTestedAgrees
Nov 18AZD9833Rule based · role ruleTestedAgrees
Nov 18AbemaciclibRule based · role ruleTestedOverridden
Nov 18RibociclibRule based · role ruleTestedOverridden
Nov 18PalbociclibRule based · role ruleTestedOverridden
Nov 18FulvestrantRule based · role ruleTestedOverridden
Nov 18LetrozoleRule based · role ruleTestedAgrees
Nov 18AnastrozoleRule based · role ruleTestedOverridden
Nov 18ExemestaneRule based · role ruleTestedOverridden
As of nowBreast NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.